Real world evidence study data published

Summary by AI BETAClose X

Renalytix plc has announced the publication of a landmark real-world evidence study in Diabetes, Obesity and Metabolism, involving 2,470 patients with type 2 diabetes and early-stage chronic kidney disease. The study demonstrates that its FDA-approved kidneyintelX.dkd test provides sustained risk prognosis, improves kidney function, increases guideline-directed therapy uptake, and measurably reduces individual patient risk trajectories over 24 months. Key findings include a 29% reduction in risk category for retested patients, a significant increase in SGLT2 inhibitor use reaching 56% in high-risk patients, and a 1.93 odds ratio for risk reduction when using therapies informed by the test. High-risk patients were also 10.4 times more likely to experience kidney function decline or failure compared to low-risk patients.

Disclaimer*

UK 100

Latest directors dealings